This month, Viatris is to realize a significant commercial boost for its interchangeable biosimilar Semglee (insulin glargine-yfgn) in the US, with the product having moved to preferred status on pharmacy benefit manager Express Scripts’ largest national formulary from 1 January 2022. (Also see "Viatris’ Interchangeable Semglee Lands On Express Scripts Formulary" - Generics Bulletin, 22 October, 2021.)
Prime Therapeutics, a PBM which serves nearly 33 million people and is collectively owned by 19 Blue Cross and Blue...